Study: NCT05363774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0519-0130
Description: SAD part: Participants will receive up to six dose levels of subcutaneous NNC0519-0130 in a sequential manner with the dose increasing between cohorts.~MAD part: The participants in first cohort will receive NNC0519-0130 subcutaneously up to 5 dose levels, and the participants in the second MAD cohort will receive NNC0519-0130 orally up to 4 dose levels.~T2D part: Participants will receive NNC0519-0130 up to two dose levels with dose escalation within the cohort.~MAD QW part: Participants will receive NNC0519-0130 up to 6 dose levels.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0519-0130
Description: SAD part: Participants will receive up to six dose levels of subcutaneous NNC0519-0130 in a sequential manner with the dose increasing between cohorts.~MAD part: The participants in first cohort will receive NNC0519-0130 subcutaneously up to 5 dose levels, and the participants in the second MAD cohort will receive NNC0519-0130 orally up to 4 dose levels.~T2D part: Participants will receive NNC0519-0130 up to two dose levels with dose escalation within the cohort.~MAD QW part: Participants will receive NNC0519-0130 up to 6 dose levels.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0519-0130
Description: SAD part: Participants will receive up to six dose levels of subcutaneous NNC0519-0130 in a sequential manner with the dose increasing between cohorts.~MAD part: The participants in first cohort will receive NNC0519-0130 subcutaneously up to 5 dose levels, and the participants in the second MAD cohort will receive NNC0519-0130 orally up to 4 dose levels.~T2D part: Participants will receive NNC0519-0130 up to two dose levels with dose escalation within the cohort.~MAD QW part: Participants will receive NNC0519-0130 up to 6 dose levels.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0519-0130
Description: SAD part: Participants will receive up to six dose levels of subcutaneous NNC0519-0130 in a sequential manner with the dose increasing between cohorts.~MAD part: The participants in first cohort will receive NNC0519-0130 subcutaneously up to 5 dose levels, and the participants in the second MAD cohort will receive NNC0519-0130 orally up to 4 dose levels.~T2D part: Participants will receive NNC0519-0130 up to two dose levels with dose escalation within the cohort.~MAD QW part: Participants will receive NNC0519-0130 up to 6 dose levels.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (NNC0519-0130)
Description: SAD part: Participants will receive up to six dose levels of subcutaneous placebo (NNC0519-0130) in a sequential manner with the dose increasing between cohorts.~MAD part: Participants in first cohort will receive placebo (NNC0519-0130) subcutaneously up to 5 dose levels, and the participants in the second MAD cohort will receive NNC0519-0130 orally up to 4 dose levels.~T2D part: Participants will receive placebo (NNC0519-0130) up to two dose levels with dose escalation within the cohort.~MAD QW part: Participants will receive Placebo up to 6 dose levels.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (NNC0519-0130)
Description: SAD part: Participants will receive up to six dose levels of subcutaneous placebo (NNC0519-0130) in a sequential manner with the dose increasing between cohorts.~MAD part: Participants in first cohort will receive placebo (NNC0519-0130) subcutaneously up to 5 dose levels, and the participants in the second MAD cohort will receive NNC0519-0130 orally up to 4 dose levels.~T2D part: Participants will receive placebo (NNC0519-0130) up to two dose levels with dose escalation within the cohort.~MAD QW part: Participants will receive Placebo up to 6 dose levels.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (NNC0519-0130)
Description: SAD part: Participants will receive up to six dose levels of subcutaneous placebo (NNC0519-0130) in a sequential manner with the dose increasing between cohorts.~MAD part: Participants in first cohort will receive placebo (NNC0519-0130) subcutaneously up to 5 dose levels, and the participants in the second MAD cohort will receive NNC0519-0130 orally up to 4 dose levels.~T2D part: Participants will receive placebo (NNC0519-0130) up to two dose levels with dose escalation within the cohort.~MAD QW part: Participants will receive Placebo up to 6 dose levels.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (NNC0519-0130)
Description: SAD part: Participants will receive up to six dose levels of subcutaneous placebo (NNC0519-0130) in a sequential manner with the dose increasing between cohorts.~MAD part: Participants in first cohort will receive placebo (NNC0519-0130) subcutaneously up to 5 dose levels, and the participants in the second MAD cohort will receive NNC0519-0130 orally up to 4 dose levels.~T2D part: Participants will receive placebo (NNC0519-0130) up to two dose levels with dose escalation within the cohort.~MAD QW part: Participants will receive Placebo up to 6 dose levels.